Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study

Michele Tinazzi, Giovanni Abbruzzese, Angelo Antonini, Roberto Ceravolo, Giovanni Fabbrini, Patrizia Lessi, Paolo Barone

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the association between clinical and socio-demographic features and anti-Parkinson drug (APD) treatment modifications in patients with PD and to describe neurologist and patient opinions regarding the need for changes in APD therapy. Methods: Subjects with PD with stable APD treatment over ≥3 months prior to baseline were enrolled and evaluated for socio-demographic data, disability, disease severity and neurologist and patient views on the need to modify APD treatment. Results: 775 Patients were included, 51% with Hoehn and Yahr (HY) stage 1-2 (early PD) and 49% with HY stage 2.5-4 (advanced PD). Neurologists modified APD treatment in 255 patients, 97 (25%) early PD and 158 (41%; p

Original languageEnglish
Pages (from-to)1130-1135
Number of pages6
JournalParkinsonism and Related Disorders
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 2013

Keywords

  • Anti-Parkinson drugs
  • Motor symptoms
  • Non-motor symptoms
  • Parkinson's disease

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study'. Together they form a unique fingerprint.

  • Cite this